ArticleBritish journal of anaesthesia2025
Targeting the kappa opioid receptor for analgesia and antitumour effects.
Article in British journal of anaesthesia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Applications of micro/nano drug delivery systems in cancer pain management.Bioactive materials · 2026Review
- κ-Opioid Receptor Agonists as Robust Pain-Modulating Agents: Mechanisms and Therapeutic Potential in Pain Modulation.Journal of clinical medicine · 2025Review
- κ-opioid receptor: from analgesic target to neuroimmune hub.Frontiers in pharmacology · 2025Review
Corrections and comments
- Retraction · 2025-01-03Date of Article and/or Notice Unknown · Notice - Limited or No Information · Removed · Temporary Removal · · date of retraction unknown, html page overwrite;
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kappa opioid (KOP) receptor agonists have analgesic actions in a range of models, but central side-effects can limit their utility. In addition, non-analgesic actions of opioid receptors are receiving significant research interest. A recent article reports that high KOP receptor expression in glioma tissue correlates with improved survival and that KOP receptor agonism further promotes apoptosis of glioma cells through regulation of the p38 MAPK oncogenic pathway. This suggests that KOP receptor ligands could be developed as chemotherapeutic adjuncts in addition to their use as analgesics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.